persistent postural-perceptual dizziness
Conditions
Interventions
L-PIVC:Repeated transcranial magnetic stimulation (rTMS) of the left brain PIVC area, high-frequency stimulation, stimulation frequency 10Hz, 100% MT, 100 pulses per set, a total of 30 sets of stimula
V1:Repeated transcranial magnetic stimulation (rTMS) of the left brain V1 area, high-frequency stimulation, stimulation frequency 10Hz, 100% MT, 100 pulses per set, a total of 30 sets of stimulation,
L-DLPFC:Repeated transcranial magnetic stimulation (rTMS) of the left brain L-DLPFC area, high-frequency stimulation, stimulation frequency 10Hz, 100% MT, 100 pulses per set, a total of 30 sets of sti
Sertraline Group:Simply administer 50mg of sertraline tablets orally once daily, without providing any other treatment measures.
Upright Group:None
Visual Phobia Group:None
Health Control Group:None
Sponsors
ShanghaiTongji Hospital (Tongji Hospital of Tongji University)
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: Part One (1) Inclusion Criteria for PPPD Patients: A total of 60 PPPD patients aged 20-70 who meet the diagnostic criteria for PPPD by the International Barany Society in 2017 were included. They were further classified into 30 cases each of visual motion-provoked type and upright posture-provoked type according to the diagnostic criteria. Symptoms have persisted for more than 6 months, and symptoms worsen with visual, upright, or movement triggers. Hamilton Depression Scale-17 (HAMD-17) score >7, Hamilton Anxiety Scale-14 (HAMA) score >7, normal cognitive function, absence of organic mental disorders, patient agreement to participate and follow-up, no significant organic lesions on head CT or MRI, and absence of organic vestibular disorders. (2) Inclusion of Control Group: 30 patients with pure generalized anxiety disorder (HAMA-14 >14), 30 patients with pure depression (HAMD-17 >14), and 30 healthy controls were included. All had normal cognitive function, agreed to participate and follow-up, and showed no significant organic lesions on head CT or MRI. Part Two Inclusion Criteria: A total of 140 PPPD patients aged 20-70 who meet the diagnostic criteria for PPPD by the International Barany Society in 2017 were included. Symptoms have persisted for more than 6 months, with HAMD-17 score >7 falling within the mild to moderate depression range, HAMA score >7, normal cognitive function, absence of organic mental disorders, patient agreement to participate and follow-up, no significant organic lesions on head CT or MRI, and absence of organic vestibular disorders.
Exclusion criteria
Exclusion criteria: Part One: Individuals with severe visual, auditory, speech impediments, and other physical illnesses who cannot complete neuropsychological tests smoothly; those with a clear history of neurological or psychiatric disorders (such as Parkinson's disease, intracranial lesions, history of brain trauma or surgery, epilepsy, schizophrenia, etc.); individuals with severe primary diseases of the liver, kidneys, hematopoietic system, and endocrine system, heavy alcohol consumption, substance abuse, and malignant tumor patients; those experiencing severe depressive episodes with clear suicidal thoughts and behaviors. Part Two: Individuals who have taken oral anti-anxiety and antidepressant medications, sedatives, flupentixol, etc., in the past two weeks, and who have severe visual, auditory, speech impediments, and other physical illnesses that hinder smooth completion of neuropsychological tests; those with a clear history of neurological or psychiatric disorders (such as Parkinson's disease, intracranial lesions, history of brain trauma or surgery, epilepsy, schizophrenia, etc.); individuals with severe primary diseases of the liver, kidneys, hematopoietic system, and endocrine system, heavy alcohol consumption, substance abuse, and malignant tumor patients; those experiencing severe depressive episodes with clear suicidal thoughts and behaviors; individuals with magnetic metals, high-conductivity metals, or artificial cochlear implants in any part of the head.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HAMD-17; | — |
Secondary
| Measure | Time frame |
|---|---|
| HAMA-14;dizziness handicap inventory;Changes in EEG and event-related potentials; | — |
Countries
CHINA
Contacts
Public ContactFu Changyong
Tongji Hospital of Tongji University
Outcome results
None listed